{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T01:56:21Z","timestamp":1791078981508,"version":"4.1.0"},"reference-count":16,"publisher":"S. Karger AG","issue":"3","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatology"],"published-print":{"date-parts":[[2021]]},"abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Background:&lt;\/i&gt;&lt;\/b&gt; Mycosis fungoides (MF) and S\u00e9zary syndrome (SS) are the most common subtypes of cutaneous T-cell lymphoma (CTCL). There is currently no cure for CTCL, and treatment is aimed at limiting disease progression. This study evaluated the efficacy and tolerability of alitretinoin in CTCL management. &lt;b&gt;&lt;i&gt;Methods:&lt;\/i&gt;&lt;\/b&gt; A retrospective, multicenter study was conducted on CTCL patients treated with alitretinoin as a primary agent or in combination with standard therapies. &lt;b&gt;&lt;i&gt;Results:&lt;\/i&gt;&lt;\/b&gt; Forty-eight patients with MF (&lt;i&gt;n&lt;\/i&gt; = 40) and SS (&lt;i&gt;n&lt;\/i&gt; = 8) with a median age of 59.7 years (\u00b114.3) were eligible for study inclusion. Treatment response data were evaluated in 40 patients and safety in 42 patients. 40.0% of the patients had early-stage, 43.8% had advanced-stage CTCL, and in 16.7% of patients there was insufficient information for staging. 40.0% (16\/40) of the patients achieved a complete or partial response, whereas 47.5% (19\/40) achieved stable disease, 12.5% (5\/40) had progressive disease, and there were no cases of disease relapses in responders. Both early and advanced stages of CTCL were responsive to alitretinoin as a primary or combined modality. Alitretinoin was well tolerated, and 64.3% (27\/42) of patients did not report any side effects. The most commonly observed side effect was hypertriglyceridemia. &lt;b&gt;&lt;i&gt;Conclusions:&lt;\/i&gt;&lt;\/b&gt; This retrospective analysis supports the efficacy and safety of alitretinoin in clearing skin disease and preventing disease progression in CTCL as a monotherapy or in combination with standard therapies. <\/jats:p>","DOI":"10.1159\/000512484","type":"journal-article","created":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T22:19:34Z","timestamp":1610403574000},"page":"479-485","source":"Crossref","is-referenced-by-count":10,"title":["Evaluation of Alitretinoin for the Treatment of Mycosis Fungoides and S\u00e9zary Syndrome"],"prefix":"10.1159","volume":"237","author":[{"given":"Raed","family":"Alhusayen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9393-3114","authenticated-orcid":false,"given":"Trang\u00a0Tuyet","family":"Vu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nouf","family":"Almuhanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Wohlmuth-Wieser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jori","family":"Hardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John-Douglas\u00a0Matthew","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Chia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Street","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil\u00a0Hartley","family":"Shear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott\u00a0Richard","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2310-8300","authenticated-orcid":false,"given":"Robert","family":"Gniadecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2021,1,11]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24876"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra032810"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2019.07.712"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy207"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2005.03.026"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2015.05.007"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2017.1309349"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.9.2456"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12684"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.0630"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.07.013"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.124607"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.140.12.1453"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2011.07637.x"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07596.x"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000709"}],"container-title":["Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/512484","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/512484","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T16:17:28Z","timestamp":1745425048000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000512484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":16,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,4,29]]},"published-print":{"date-parts":[[2021,5,3]]}},"URL":"https:\/\/doi.org\/10.1159\/000512484","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.13553654","asserted-by":"subject"}]},"ISSN":["1018-8665","1421-9832"],"issn-type":[{"value":"1018-8665","type":"print"},{"value":"1421-9832","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]}}}